Definium Therapeutics (NASDAQ:DFTX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Definium Therapeutics (NASDAQ:DFTX) had its price target boosted by equities research analysts at Stifel Nicolaus from $30.00 to $60.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 34.89% from the company’s current price.

Other equities analysts have also recently issued reports about the company. Piper Sandler reissued an “overweight” rating and set a $48.00 target price (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. Needham & Company LLC raised their price objective on Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, June 23rd. JonesTrading boosted their target price on Definium Therapeutics from $61.00 to $74.00 and gave the company a “buy” rating in a research report on Wednesday, June 24th. Robert W. Baird increased their target price on Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 23rd. Finally, Canaccord Genuity Group set a $58.00 price target on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $49.23.

Definium Therapeutics Price Performance

Shares of NASDAQ DFTX opened at $44.48 on Wednesday. Definium Therapeutics has a fifty-two week low of $7.54 and a fifty-two week high of $49.20. The stock has a fifty day moving average of $27.65 and a 200-day moving average of $21.01. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69. The stock has a market cap of $4.43 billion, a PE ratio of -17.86 and a beta of 2.20.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Equities research analysts anticipate that Definium Therapeutics will post -2.29 earnings per share for the current year.

Insider Buying and Selling at Definium Therapeutics

In other Definium Therapeutics news, insider Matthew T. Wiley sold 2,867 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the transaction, the insider directly owned 174,633 shares of the company’s stock, valued at approximately $7,863,723.99. The trade was a 1.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark Sullivan sold 13,008 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the sale, the insider directly owned 320,571 shares in the company, valued at $14,435,312.13. This trade represents a 3.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 48,096 shares of company stock valued at $2,165,763 in the last three months. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

A number of hedge funds have recently made changes to their positions in DFTX. Royal Bank of Canada lifted its stake in shares of Definium Therapeutics by 10.4% in the first quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock worth $382,000 after buying an additional 6,148 shares in the last quarter. Creative Planning boosted its holdings in shares of Definium Therapeutics by 2.6% during the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after purchasing an additional 1,655 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Definium Therapeutics by 5.1% in the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after purchasing an additional 2,342 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Definium Therapeutics by 6.3% in the second quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after purchasing an additional 6,839 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares in the last quarter. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.